Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLS-1488 in advanced solid tumors
NCT05902988Phase 2Recruiting
- Sponsor
- Volastra Therapeutics
- Start
- Oct 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of VLS-1488 in High-Grade Serous Ovarian Carcinoma (HGSOC), squamous cell carcinoma of the lung (SCCL), triple-negative breast cancer (TNBC) and 11 more (4 arms), sponsored by Volastra Therapeutics. Primary endpoints: Dose Limiting Toxicities at 12 months, Maximum Tolerated Dose at 12 months and 6 more. Started Oct 2023; status: recruiting.
02
Drugs
VLS-1488
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)squamous cell carcinoma of the lung (SCCL)triple-negative breast cancer (TNBC)gastric adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05902988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05902988.